Hot Features
| Actionnaire | Type | Détenues (Réel) | % en Circulation | Valeur Marchande | Date de Reporte |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, LP | Institution | 6 652 013 | 13,98% | US$ 205,61M | 2026-03-31 |
| Frazier Life Sciences X, L.P. | Institution | 5 219 440 | 10,97% | US$ 161,33M | 2025-09-26 |
| OrbiMed Advisors LLC | Institution | 3 637 887 | 7,64% | US$ 112,45M | 2026-03-31 |
| New Enterprise Associates, Inc. | Institution | 3 614 486 | 7,59% | US$ 111,72M | 2026-03-31 |
| New Enterprise Associates 17, L.P. | Institution | 3 614 486 | 7,59% | US$ 111,72M | 2025-11-10 |
| Wellington Management Group LLP | Institution | 3 191 824 | 6,71% | US$ 98,66M | 2026-03-31 |
| Orbimed Private Investments VII, LP | Institution | 2 958 000 | 6,21% | US$ 91,43M | 2026-02-11 |
| BlackRock, Inc. | Institution | 2 941 406 | 6,18% | US$ 90,92M | 2026-03-31 |
| FMR LLC | Institution | 2 936 684 | 6,17% | US$ 90,77M | 2026-03-31 |
| Deep Track Capital, LP | Institution | 2 757 569 | 5,79% | US$ 85,24M | 2026-03-31 |
| Deep Track Biotechnology Master Fund, Ltd | Institution | 2 188 592 | 4,60% | US$ 67,65M | 2025-06-30 |
| Norwest Venture Partners XVI, LP. | Institution | 2 136 335 | 4,49% | US$ 66,03M | 2025-09-26 |
| NVP Associates, LLC | Institution | 2 136 335 | 4,49% | US$ 66,03M | 2026-03-31 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | Institution | 2 017 394 | 4,24% | US$ 62,36M | 2025-09-30 |
| Polar Capital Holdings Plc | Institution | 1 622 186 | 3,41% | US$ 50,14M | 2026-03-31 |
| Braidwell LP | Institution | 1 492 467 | 3,14% | US$ 46,13M | 2026-03-31 |
| Vanguard Capital Management, LLC | Institution | 1 477 592 | 3,10% | US$ 45,67M | 2026-03-31 |
| Mr. Peter Hawryluk | Initiés | 1 214 444 | 2,55% | US$ 37,54M | 2026-05-06 |
| Aaron Wealth Advisors LLC | Institution | 1 168 176 | 2,45% | US$ 36,11M | 2026-03-31 |
| Cormorant Asset Management, LP | Institution | 1 120 000 | 2,35% | US$ 34,62M | 2026-03-31 |
| Frazier Life Sciences Public Fund, L.P. | Institution | 1 103 920 | 2,32% | US$ 34,12M | 2025-09-26 |
| T. Rowe Price Group, Inc. | Institution | 1 029 007 | 2,16% | US$ 31,81M | 2026-03-31 |
| Driehaus Capital Management LLC | Institution | 1 018 212 | 2,14% | US$ 31,47M | 2026-03-31 |
| Kynam Capital Management, LP | Institution | 934 799 | 1,96% | US$ 28,89M | 2026-03-31 |
| Citadel Advisors LLC | Institution | 932 833 | 1,96% | US$ 28,83M | 2026-03-31 |
| Woodline Partners LP | Institution | 900 063 | 1,89% | US$ 27,82M | 2026-03-31 |
| Eventide Asset Management, LLC | Institution | 890 000 | 1,87% | US$ 27,51M | 2026-03-31 |
| Caligan Partners, LP | Institution | 848 590 | 1,78% | US$ 26,23M | 2026-03-31 |
| Parkman Healthcare Partners LLC | Institution | 800 037 | 1,68% | US$ 24,73M | 2026-03-31 |
| State Street Global Advisors, Inc. | Institution | 787 208 | 1,65% | US$ 24,33M | 2026-03-31 |
| EcoR1 Capital, LLC | Institution | 777 000 | 1,63% | US$ 24,02M | 2026-03-31 |
| OrbiMed Genesis Master Fund, L.P. | Institution | 679 887 | 1,43% | US$ 21,02M | 2026-02-11 |
| Geode Capital Management, LLC | Institution | 670 385 | 1,41% | US$ 20,72M | 2026-03-31 |
| TCG Crossover Management, LLC | Institution | 650 000 | 1,37% | US$ 20,09M | 2026-03-31 |
| Millennium Management LLC | Institution | 564 415 | 1,19% | US$ 17,45M | 2026-03-31 |
| StemPoint Capital LP | Institution | 499 469 | 1,05% | US$ 15,44M | 2026-03-31 |
| The Goldman Sachs Group, Inc. | Institution | 425 546 | 0,89% | US$ 13,15M | 2026-03-31 |
| UBS Asset Management AG | Institution | 354 152 | 0,74% | US$ 10,95M | 2026-03-31 |
| Frazier Life Sciences Public Overage Fund, L.P. | Institution | 325 653 | 0,68% | US$ 10,07M | 2025-09-26 |
| Candriam, Société En Commandite Par Actions | Institution | 294 374 | 0,62% | US$ 9,10M | 2026-03-31 |
| Vanguard Portfolio Management, LLC | Institution | 293 295 | 0,62% | US$ 9,07M | 2026-03-31 |
| D. E. Shaw & Co., L.P. | Institution | 288 889 | 0,61% | US$ 8,93M | 2026-03-31 |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.